Product nameAnti-PSAP antibody [EPR10784(B)]
See all PSAP primary antibodies
DescriptionRabbit monoclonal [EPR10784(B)] to PSAP
Tested applicationsSuitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt,ICC/IF or IP
Species reactivityReacts with: Human
Synthetic peptide corresponding to residues in Human PSAP (UniProt P07602).
- 293T, HepG2, A431, HeLa cell lysate. Human colon tissue. Human transitional call carcinoma tissue.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.
This product is a recombinant rabbit monoclonal antibody.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab166910 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 58 kDa.|
|IHC-P||1/50 - 1/100.|
FunctionThe lysosomal degradation of sphingolipids takes place by the sequential action of specific hydrolases. Some of these enzymes require specific low-molecular mass, non-enzymic proteins: the sphingolipids activator proteins (coproteins).
Saposin-A and saposin-C stimulate the hydrolysis of glucosylceramide by beta-glucosylceramidase (EC 22.214.171.124) and galactosylceramide by beta-galactosylceramidase (EC 126.96.36.199). Saposin-C apparently acts by combining with the enzyme and acidic lipid to form an activated complex, rather than by solubilizing the substrate.
Saposin-B stimulates the hydrolysis of galacto-cerebroside sulfate by arylsulfatase A (EC 188.8.131.52), GM1 gangliosides by beta-galactosidase (EC 184.108.40.206) and globotriaosylceramide by alpha-galactosidase A (EC 220.127.116.11). Saposin-B forms a solubilizing complex with the substrates of the sphingolipid hydrolases.
Saposin-D is a specific sphingomyelin phosphodiesterase activator (EC 18.104.22.168).
Involvement in diseaseDefects in PSAP are the cause of combined saposin deficiency (CSAPD) [MIM:611721]; also known as prosaposin deficiency. CSAPD is due to absence of all saposins, leading to a fatal storage disorder with hepatosplenomegaly and severe neurological involvement.
Defects in PSAP saposin-B region are the cause of leukodystrophy metachromatic due to saposin-B deficiency (MLD-SAPB) [MIM:249900]. MLD-SAPB is an atypical form of metachromatic leukodystrophy. It is characterized by tissue accumulation of cerebroside-3-sulfate, demyelination, periventricular white matter abnormalities, peripheral neuropathy. Additional neurological features include dysarthria, ataxic gait, psychomotr regression, seizures, cognitive decline and spastic quadriparesis.
Defects in PSAP saposin-C region are the cause of atypical Gaucher disease (AGD) [MIM:610539]. Affected individuals have marked glucosylceramide accumulation in the spleen without having a deficiency of glucosylceramide-beta glucosidase characteristic of classic Gaucher disease, a lysosomal storage disorder.
Defects in PSAP saposin-A region are the cause of atypical Krabbe disease (AKRD) [MIM:611722]. AKRD is a disorder of galactosylceramide metabolism. AKRD features include progressive encephalopathy and abnormal myelination in the cerebral white matter resembling Krabbe disease.
Note=Defects in PSAP saposin-D region are found in a variant of Tay-Sachs disease (GM2-gangliosidosis).
Sequence similaritiesContains 2 saposin A-type domains.
Contains 4 saposin B-type domains.
modificationsThis precursor is proteolytically processed to 4 small peptides, which are similar to each other and are sphingolipid hydrolase activator proteins.
N-linked glycans show a high degree of microheterogeneity.
The one residue extended Saposin-B-Val is only found in 5% of the chains.
- Information by UniProt
- A1 activator antibody
- Cerebroside sulfate activator antibody
- Co-beta-glucosidase antibody
All lanes : Anti-PSAP antibody [EPR10784(B)] (ab166910) at 1/10000 dilution
Lane 1 : 293T cell lysate
Lane 2 : HepG2 cell lysate
Lane 3 : A431 cell lysate
Lane 4 : HeLa cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 58 kDa
Immunohistochemical analysis of paraffin-embedded Human colon tissue labeling PSAP with ab166910 at 1/50 dilution.
Immunohistochemical analysis of paraffin-embedded Human transitional cell carcinoma labeling PSAP with ab166910 at 1/50 dilution.
This product has been referenced in:
- Oldoni F et al. Naturally Occurring Variants in LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Affect HDL (High-Density Lipoprotein) Metabolism Through ABCA1 (ATP-Binding Cassette A1) and SR-B1 (Scavenger Receptor Class B Type 1) in Humans. Arterioscler Thromb Vasc Biol 38:1440-1453 (2018). Read more (PubMed: 29853565) »
- Lu Q et al. A novel probe to assess cytosolic entry of exogenous proteins. Nat Commun 9:3104 (2018). Read more (PubMed: 30082832) »